Novartis annoiunces positive data from Phase III studies of AIN457 in clearing skin of psoriasis...
This data was presented at the European Association of Dermatology and Venereology (EADV) Congress, in Amsterdam, Netherlands. Secukinumab’s new mode of action stops interleukin-17A (IL-17A), which...
pharmaceutical-business-review.com